NuCana plc Discontinues NuTide:323 Study
Ticker: NCNA · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-discontinuation, pipeline-update, pharmaceutical
TL;DR
NuCana just pulled the plug on the NuTide:323 study. Big implications for their pipeline.
AI Summary
NuCana plc announced on August 29, 2024, that it is discontinuing the NuTide:323 study. This decision was made following a review of the study's progress and data, though specific reasons or financial impacts were not detailed in this filing.
Why It Matters
The discontinuation of a clinical study can significantly impact a company's pipeline and future revenue projections, potentially affecting investor confidence.
Risk Assessment
Risk Level: medium — Discontinuing a clinical trial can indicate issues with efficacy, safety, or strategic direction, posing a risk to the company's future development and financial health.
Key Players & Entities
- NuCana plc (company) — Registrant
- NuTide:323 (study) — Clinical trial being discontinued
- August 29, 2024 (date) — Date of announcement
FAQ
What was the specific reason for discontinuing the NuTide:323 study?
The filing states the study is being discontinued following a review, but does not specify the exact reasons.
When was the decision to discontinue the study announced?
The decision was announced on August 29, 2024.
What is the primary business of NuCana plc?
NuCana plc is involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
Where is NuCana plc headquartered?
NuCana plc is headquartered at 3 Lochside Way, Edinburgh EH12 9DT, United Kingdom.
Does NuCana plc file annual reports on Form 20-F?
Yes, the filing indicates that NuCana plc files annual reports under Form 20-F.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 19.1 · Accepted 2024-08-29 16:17:27
Filing Documents
- d849784d6k.htm (6-K) — 11KB
- d849784dex991.htm (EX-99.1) — 12KB
- 0001193125-24-209923.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. NuCana plc By: /s/ Donald Munoz Name: Donald Munoz Title: Chief Financial Officer Date: August 29, 2024